Black Diamond Therapeutics (BDTX) AI Stock Analysis

• Market Cap: $78.76M
• Dividend Yield: N/A
• Average Volume (3M): 6.01M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.96
• Revenue Growth: N/A
• EPS Growth: 33.97%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -1.27
• Shares Outstanding: 56,662,224
• 10 Day Avg. Volume: 1,587,258
• 30 Day Avg. Volume: 6,011,559
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 33.05
• Price to Cash Flow (P/CF): -1.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $13.50
• Price Target Upside: 871.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Black Diamond Therapeutics has significant financial challenges, with zero revenue and negative cash flows, reflecting a high-risk profile. The technical indicators suggest weak market momentum. However, the recent partnership with Servier offers a positive outlook, providing potential financial inflows and strategic positioning in the oncology market.

Positive Factors

Clinical Trials

BDTX-1535 has shown robust activity in both C797S and PACC non-classical EGFR+ NSCLC, with ORRs of 40% and 44% that are encouraging and competitive with alternative non-targeted therapies.

Safety Profile

The safety profile of BDTX-1535 is consistent with approved EGFR TKI class of drugs, with no cases of severe side effects like G3/4 diarrhea or off-target effects.

Negative Factors

Financial Performance

Black Diamond reported a net loss of $0.28 per share, which is narrower than the prior estimated net loss of $0.37 per share, predominantly due to lower-than-anticipated operating expenses.

Risks

Risks include negative efficacy data for BDTX-1535 or BDTX-4933 and poorer than expected efficacy or safety profiles.

Black Diamond Therapeutics Business Overview & Revenue Model

Company Description

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Black Diamond Therapeutics makes money primarily through the development and commercialization of its pharmaceutical products targeting specific mutations in cancer treatment. The company generates revenue by advancing its proprietary drug candidates through clinical trials, seeking regulatory approval, and ultimately bringing these therapies to market. Significant revenue streams may include sales of approved drugs, partnerships, and collaborations with larger pharmaceutical companies for co-development and commercialization efforts. Additionally, the company may receive milestone payments and royalties from licensing agreements, providing a diversified approach to revenue generation. However, as a biotechnology company in the clinical development stage, Black Diamond Therapeutics may also rely on funding from investors and financial markets until its products are commercially available.

Black Diamond Therapeutics Financial Statement Overview

Summary

Black Diamond Therapeutics is facing significant financial challenges, characterized by zero revenue generation, negative equity, and persistent negative cash flows. The company may depend heavily on financing activities to sustain operations, which poses a high-risk profile typical for early-stage biotechnology firms.

Income Statement

The company has consistently reported zero revenue over the years, indicating a lack of commercialized products or services. This results in gross profit and net income being highly negative. The EBIT and EBITDA margins are unavailable due to zero revenue, and the overall income statement shows a persistent negative net income trend.

Balance Sheet

The balance sheet reveals a challenging financial position with negative stockholders' equity for multiple years, indicating financial instability. The debt-to-equity ratio is not applicable due to negative equity, and the company has high liabilities relative to its assets. The equity ratio is also negative, underscoring the precarious financial health.

Cash Flow

Operating cash flow is consistently negative, reflecting ongoing cash burn without revenue generation. While there is some positive movement in investing and financing cash flows, the free cash flow remains negative with no growth, suggesting a reliance on external funding to sustain operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-437.00K	-3.24M	-2.22M	-600.00K
	EBIT
-78.78M	-86.46M	-92.83M	-126.87M	-69.57M
	EBITDA
-78.78M	-86.02M	-92.32M	-126.67M	-66.65M
	Net Income Common Stockholders
-69.68M	-82.44M	-84.52M	-123.20M	-65.48M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
98.58M	131.40M	122.81M	209.79M	315.07M
	Total Assets
122.64M	158.57M	156.25M	247.68M	329.67M
	Total Debt
18.78M	25.30M	28.14M	28.46M	8.74M
	Net Debt
-17.66M	-30.92M	-6.17M	-37.34M	-25.86M
	Total Liabilities
39.35M	41.83M	40.56M	491.50M	21.91M
	Stockholders Equity
83.28M	116.74M	-334.99M	-243.82M	-118.22M
Cash Flow		Free Cash Flow
-62.30M	-66.75M	-85.27M	-102.86M	-52.29M
	Operating Cash Flow
-62.30M	-66.72M	-85.08M	-100.15M	-52.15M
	Investing Cash Flow
16.97M	16.35M	53.37M	130.61M	-281.69M
	Financing Cash Flow
25.55M	71.93M	177.00K	729.00K	214.94M

Black Diamond Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.39
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDTX, the sentiment is Negative. The current price of 1.39 is below the 20-day moving average (MA) of 1.57, below the 50-day MA of 1.90, and below the 200-day MA of 3.42, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 38.24 is Neutral, neither overbought nor oversold. The STOCH value of 49.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDTX.

Black Diamond Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OCX	55 Neutral	$79.51M	―	-910.86%	―	25.15%	81.47%
Sector *	48 Neutral	$6.36B	1.19	-46.31%	2.67%	19.41%	1.23%
AVTX	45 Neutral	$52.29M	―	-50.06%	―	-77.09%	63.49%
ATOS	39 Underperform	$83.46M	―	-31.39%	―	―	15.09%
BDTX	38 Underperform	$78.76M	―	-69.67%	―	―	33.97%
VOR	34 Underperform	$87.40M	―	-94.52%	―	―	2.98%
ELTX	29 Underperform	$79.77M	―	-9999.00%	―	―	27.65%

Black Diamond Therapeutics Corporate Events

Black Diamond Therapeutics Partners with Servier for BDTX-4933

On March 18, 2025, Black Diamond Therapeutics entered into a License Agreement with Servier Pharmaceuticals, granting Servier a worldwide license to develop and commercialize BDTX-4933, a small molecule targeting RAF/RAS-mutant solid tumors. This agreement includes an upfront payment of $70 million to Black Diamond and potential milestone payments up to $710 million, along with royalties. Servier will lead the development and commercialization of BDTX-4933, which is currently in Phase 1 trials, with applications in non-small cell lung cancer and other solid tumors. This strategic partnership aims to address unmet medical needs in oncology and enhance Black Diamond’s position in the industry.